Inventiva Announced That The Underwriters Of The Previously Announced Public Offering Have Exercised In Full Their Option To Purchase 5.84M Additional American Depositary Shares
Benzinga Newsdesk 11 months ago
BiotechNewsHealth CareFinancingGeneral
Following the exercise in full of the Underwriters' Option, the total number of ADSs issued in the Offering will amount to 44,805,193, resulting in gross proceeds for the Company of approximately $172.5 million (€149.0
Following the exercise in full of the Underwriters' Option, the total number of ADSs issued in the Offering will amount to 44,805,193, resulting in gross proceeds for the Company of approximately $172.5 million (€149.0 million1) and the estimated net proceeds of the Offering, after deducting underwriting fees, commissions and estimated expenses payable by the Company, will be approximately of $161.2 million (€139.3 million).
The Company intends to apply the net proceeds from the sale of Additional ADSs on a pro rata basis to the use of proceeds identified with respect to the base offering.
The offering price of $3.85 per ADS and Additional ADS (corresponding to €3.33 per ordinary share based on the exchange rate of €1.00 = $1.1576 as published by the European Central Bank on November 12, 2025) is equal to the volume-weighted average price of the share of the Company on the regulated market of Euronext in Paris ("Euronext") for the last trading session preceding the pricing date of the Offering, less a discount of 0.89%. The offering price was determined by the Chief Executive Officer in accordance with a sub-delegation of powers from the Company's Board of Directors (Conseil d'Administration) on October 27, 2025, pursuant to the 25th resolution of the Company's combined shareholders' meeting held on May 22, 2025
